{"product_id":"emergentbiosolutions-pestle-analysis","title":"Emergent BioSolutions PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain strategic advantage with our PESTLE Analysis of Emergent BioSolutions—concise, up-to-date insights into political, economic, social, technological, legal, and environmental forces shaping the company. Use these findings to refine investment decisions, risk assessments, and growth strategies. Purchase the full report for the complete, editable analysis and actionable recommendations you can deploy immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment biodefense funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue is highly exposed to U.S. and allied biodefense appropriations and emergency supplements; BARDA's FY2024 budget (~$1.3B) and DoD\/ASPR procurement cycles drive demand visibility and capacity planning. Shifts in congressional priorities or election outcomes can accelerate or delay awards, impacting timing of recognitions. Multi‑year IDIQ contracts provide backbone stability, but continuing resolutions create meaningful timing risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic stockpile priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic National Stockpile replenishment choices directly shape demand volumes for vaccines, antitoxins and chemical countermeasures, with policy emphasis on all‑hazards preparedness expanding product breadth while austerity narrows it. Post‑incident reviews frequently reweight allocations between biologic and chemical threats, altering procurement priorities and contract timing. International stockpiles such as NATO and EU rescEU provide political diversification of demand and procurement partners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitics and biosecurity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeightened geopolitical tensions elevate CBRN readiness and dual‑use scrutiny, increasing demand for biodefense capabilities. Export controls from regimes like the Australia Group (43 members) and national security clearances constrain facility locations and tech transfer. Partnerships with US and allied defense agencies require strict handling of classified and sensitive data. Alignment with WHO\/IHR (196 States Parties) shapes cross‑border cooperation and access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic–private partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic–private partnerships in 2024 featured advanced market commitments and milestone payments that de-risk capacity investments, supporting scale‑up for biologics and countermeasures. Transparent procurement and performance metrics increasingly drive reputation and repeat awards. Localization preferences are prompting regional manufacturing footprints and coalition engagement shapes standards and funding flows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ede‑risking: milestone payments, advanced market commitments (2024 focus)\u003c\/li\u003e\n\u003cli\u003eprocurement: transparent KPIs influence repeat awards\u003c\/li\u003e\n\u003cli\u003elocalization: regional plants to meet buy‑local rules\u003c\/li\u003e\n\u003cli\u003ecoalitions: preparedness networks shaping funding and standards\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade and industrial policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuy‑American and reshoring incentives such as the Inflation Reduction Act (about 369 billion USD) and the CHIPS and Science Act (about 280 billion USD) favor domestic Emergent sites but complicate multi‑sourcing and supplier networks.\u003c\/p\u003e\n\u003cp\u003eSection 301 tariffs (up to 25%) on some imports raise bioprocess COGS and delay equipment deliveries; H‑1B cap of 85,000 and visa backlogs constrain specialized hires; pandemic lessons have driven larger BARDA and advance‑purchase mechanisms, institutionalizing surge retainers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIRA 369B; CHIPS 280B\u003c\/li\u003e\n\u003cli\u003eSection 301 tariffs up to 25%\u003c\/li\u003e\n\u003cli\u003eH‑1B cap 85,000\u003c\/li\u003e\n\u003cli\u003eIncreased BARDA\/advance‑purchase surge funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiodefense appropriations, \u003cstrong\u003e$1.3B\u003c\/strong\u003e BARDA, IRA \u003cstrong\u003e$369B\u003c\/strong\u003e, CHIPS \u003cstrong\u003e$280B\u003c\/strong\u003e shift domestic supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmergent's revenue and capacity hinge on US biodefense appropriations and BARDA\/DoD procurement cycles (BARDA FY2024 ~$1.3B), while congressional shifts and continuing resolutions create timing risk. Buy‑American incentives (IRA 369B, CHIPS 280B) favor domestic sites; tariffs and visa caps raise costs and hiring constraints.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBARDA FY2024\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflation Reduction Act\u003c\/td\u003e\n\u003ctd\u003e$369B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCHIPS \u0026amp; Science Act\u003c\/td\u003e\n\u003ctd\u003e$280B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSection 301 tariffs\u003c\/td\u003e\n\u003ctd\u003eup to 25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eH‑1B cap\u003c\/td\u003e\n\u003ctd\u003e85,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces—Political, Economic, Social, Technological, Environmental and Legal—uniquely impact Emergent BioSolutions, combining data-backed trends, region- and industry-specific examples, forward-looking insights and scenario guidance to help executives and investors identify risks, opportunities and strategic responses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondensed Emergent BioSolutions PESTLE analysis that organizes political, economic, social, technological, legal and environmental risks for quick reference—ideal for meetings or slide decks. Easily shareable and editable so teams can annotate region- or product-specific insights to speed decision-making and risk alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFunding cyclicality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCountermeasure demand is highly cyclical, spiking during events such as the 2020 COVID-19 surge and normalizing in subsequent years, so scenario planning must model prolonged troughs in non‑crisis periods. Maintaining a multi‑product portfolio and CDMO services provides revenue diversification to smooth cash flow between spikes. Revenue visibility hinges on the quality of backlog and exercised contract options, making option structures and firm orders critical to forecasting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and cost structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInput-cost inflation—CPI ~3.4% in 2024—has translated into material price pressure: industry reports show single‑use systems and biologics media cost increases up to ~15–20%, squeezing margins. Energy cost volatility and long‑lead equipment plus validation raise capex intensity and extend payback timelines. Government contract indexation often lags market inflation, creating margin exposure. Lean operations and digitalization are essential to offset rising unit costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO market dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCDMO demand for biologics and vaccines drives higher utilization of fill‑finish and drug‑substance assets, with the global CDMO market surpassing $100 billion in 2024. Pricing remains highly sensitive to capacity supply, client funding cycles and biotech capital markets. Securing late‑stage and commercial programs stabilizes revenues versus early‑stage volatility. Competitive differentiation hinges on proven quality track records and speed to clinic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency and global sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eForeign exchange affects international tenders and input costs for Emergent BioSolutions, influencing bid competitiveness and COGS. Hedging policies mitigate but cannot eliminate volatility; in 2024 the US dollar strengthened about 5% versus a basket of major currencies, increasing translation exposure. Contract currency mix and natural hedges like local pricing matter, and geographical diversification helps balance macro cycles.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFX impact on tenders and COGS\u003c\/li\u003e\n\u003cli\u003eHedging reduces but not eliminates volatility\u003c\/li\u003e\n\u003cli\u003eContract currency mix \u0026amp; natural hedges critical\u003c\/li\u003e\n\u003cli\u003eGeographical diversification balances macro cycles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rates and capital access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHigher rates (Fed funds ~5.25–5.50% mid‑2025) raise financing costs for Emergent's upgrades, remediation and expansion, lifting interest expense and capex hurdle rates; 2024 revenue was about $1.09B and market cap near $1.6B, so capital efficiency matters. Debt covenants can constrain flexibility during revenue dips, while public equity conditions shape M\u0026amp;A and equity raise options; prioritizing ROIC on new capacity is critical.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher rates ↑ financing costs\u003c\/li\u003e\n\u003cli\u003eDebt covenants limit flexibility\u003c\/li\u003e\n\u003cli\u003eEquity markets affect M\u0026amp;A\u003c\/li\u003e\n\u003cli\u003ePrioritize ROIC on capacity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiodefense appropriations, \u003cstrong\u003e$1.3B\u003c\/strong\u003e BARDA, IRA \u003cstrong\u003e$369B\u003c\/strong\u003e, CHIPS \u003cstrong\u003e$280B\u003c\/strong\u003e shift domestic supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDemand is highly cyclical with 2024 revenue ~$1.09B and reliance on contracted orders; CDMO market \u0026gt;$100B in 2024 stabilizes fill‑finish demand. Input inflation (CPI ~3.4% in 2024) and single‑use cost rises (~15–20%) squeeze margins while Fed funds ~5.25–5.50% mid‑2025 increases financing costs; USD strengthened ~5% in 2024 affecting COGS and tenders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue 2024\u003c\/td\u003e\n\u003ctd\u003e$1.09B\u003c\/td\u003e\n\u003ctd\u003eVisibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO market 2024\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$100B\u003c\/td\u003e\n\u003ctd\u003eDemand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPI 2024\u003c\/td\u003e\n\u003ctd\u003e~3.4%\u003c\/td\u003e\n\u003ctd\u003eCost pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds mid‑2025\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003ctd\u003eFinancing cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD 2024\u003c\/td\u003e\n\u003ctd\u003e+~5%\u003c\/td\u003e\n\u003ctd\u003eFX exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eEmergent BioSolutions PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact PESTLE analysis for Emergent BioSolutions you’ll receive after purchase—fully formatted and ready to use. It contains the complete political, economic, social, technological, legal, and environmental assessment as displayed, with no placeholders or teasers. After checkout you’ll instantly download this identical, professionally structured file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162553266553,"sku":"emergentbiosolutions-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/emergentbiosolutions-pestle-analysis.png?v=1762703112","url":"https:\/\/portersfiveforce.com\/products\/emergentbiosolutions-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}